CFDE Data Portal | Search ALG1L10P

	Label	Description
	ALG1L10P Gene (Entity type)	ENSG00000254016 - ALG1 like 10, pseudogene
	GSE236502 paclitaxel 2 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE126529 MYC inhibition B cell 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE224105 GSE224108 zearalenone 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182150 KIT LSD1 MYC inhibition 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE126529 MYC inhibition B cell 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	ADCK4 IDG kinase ARCHS4 coexpression Gene Set (Entity type)	A Gene Set from IDG
	GTEx Colon 20-29 vs 30-39 Up Gene Set (Entity type)	A Gene Set from GTEx
	GSE236502 paclitaxel 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE153158 NF-kB knockout U-937 6 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS

ALG1L10P

ENSG00000254016 - ALG1 like 10, pseudogene

GSE236502 paclitaxel 2 v 3 human up

A Gene Set from LINCS

GSE126529 MYC inhibition B cell 1 v 0 human dn

A Gene Set from LINCS

GSE224105 GSE224108 zearalenone 3 v 2 human dn

A Gene Set from LINCS

GSE182150 KIT LSD1 MYC inhibition 2 v 5 human up

A Gene Set from LINCS

GSE126529 MYC inhibition B cell 1 v 2 human dn

A Gene Set from LINCS

ADCK4 IDG kinase ARCHS4 coexpression

A Gene Set from IDG

GTEx Colon 20-29 vs 30-39 Up

A Gene Set from GTEx

GSE236502 paclitaxel 2 v 0 human up

A Gene Set from LINCS

GSE153158 NF-kB knockout U-937 6 v 2 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.